<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03691844</url>
  </required_header>
  <id_info>
    <org_study_id>AMZ001-006</org_study_id>
    <nct_id>NCT03691844</nct_id>
  </id_info>
  <brief_title>AMZ001 for the Treatment of Knee Osteoarthritis Symptoms</brief_title>
  <official_title>A Placebo-controlled, Double-blind, Randomized, Trial of AMZ001 for the Treatment of Knee Osteoarthritis Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amzell</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amzell</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled, parallel group, 4-week&#xD;
      trial of a formulation of AMZ001 once or twice daily versus placebo twice daily, including a&#xD;
      single-blind treatment group with a commercial gel four times daily.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled, parallel group, 4-week&#xD;
      trial of a formulation of AMZ001 once or twice daily versus placebo twice daily, including a&#xD;
      single-blind treatment group with a commercial gel four times daily. Participants will be&#xD;
      evaluated for osteoarthritis by X-ray images of the knees and one knee will be selected for&#xD;
      treatment as the target knee. The study gel will be applied directly to that knee throughout&#xD;
      the 4 weeks of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 4, 2018</start_date>
  <completion_date type="Actual">July 9, 2019</completion_date>
  <primary_completion_date type="Actual">July 9, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>placebo-controlled, double-blind, randomized, parallel study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>3 treatment arms will be double-blind, the 4th (comparator) will be single-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>WOMAC Pain Sub-score</measure>
    <time_frame>baseline, week 4</time_frame>
    <description>Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain sub-score (questions 1-5; score 0 [no pain]-50 [extreme pain]) on target knee. The WOMAC scores were normalized to a 0-100 point scale for data analysis, where higher scores indicate greater pain, stiffness or difficulty in performing daily tasks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>WOMAC Total Score and WOMAC Function and Stiffness</measure>
    <time_frame>baseline, week 4</time_frame>
    <description>Change from baseline in Western Ontario McMasters Universities Osteoarthritis Index (WOMAC) total score and WOMAC function (degree of difficulty experienced in performing daily activities - 17 questions score 0-170) and stiffness (the degree and timing of joint stiffness - 2 questions score 0-20). The WOMAC scores were normalized to a 0-100 point scale for data analysis, where 0 is no pain and higher scores indicate greater pain, stiffness or difficulty in performing daily tasks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC Pain Weight-bearing Score and Non-weight-bearing Score</measure>
    <time_frame>baseline, week 4</time_frame>
    <description>Change from baseline in Western Ontario McMasters Universities Osteoarthritis Index (WOMAC) pain weight-bearing score (questions 1,2, &amp; 5; score 0-30) and non-weight-bearing score (questions 3&amp;4; score 0-20) on target knee. The WOMAC scores were normalized to a 0-100 point scale for data analysis, where 0 is no pain and higher scores indicate greater pain, stiffness or difficulty in performing daily tasks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICOAP Scores</measure>
    <time_frame>baseline, week 4</time_frame>
    <description>Change from baseline in Intermittent and Constant Osteoarthritis Pain (ICOAP) scores (score 0 [no pain]- 4 [extreme pain]). ICOAP scores were normalized to a 0-100 point scale, where 0 is no pain and higher scores indicate greater pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Function</measure>
    <time_frame>baseline, week 4</time_frame>
    <description>Change in baseline in physical function assessed by the chair-stand test. The test measures the maximum number of chair stand repetitions possible in a 30-second period with out using the arms. Where 0 is no repetition completed and higher numbers corresponds to greater repetitions and physical function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Responders as Per OMERACT-OARSI Criteria</measure>
    <time_frame>week 4</time_frame>
    <description>Outcome Measures in Rheumatology- Osteoarthritis Research Society International (OMERACT-OARSI) response involves changes that are deemed to be clinically relevant in three domains: pain, function, and PGA (Patient Global Assessment). For each of these domains, ranges are defined for absolute and percent changes from baseline that correspond to &quot;high improvement&quot; and &quot;moderate improvement&quot;. OMERACT-OARSI response is defined as either high improvement in at least 1 of WOMAC pain and function scores OR moderate improvement in at least 2 of WOMAC pain scores, WOMAC function score or Patient Global Assessment (PGA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Dose of Rescue Medication</measure>
    <time_frame>weeks 1 through 4</time_frame>
    <description>Total dose of rescue medication calculated as the average gram use/day, based on pill counts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Between Baseline and First Use of Rescue Medication</measure>
    <time_frame>weeks 1 through 4</time_frame>
    <description>Time between baseline and first use of rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC Pain Sub-score (Dose Comparison)</measure>
    <time_frame>baseline, week 4</time_frame>
    <description>Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain sub-score (questions 1-5; score 0 [no pain]-50 [extreme pain]) on target knee. The WOMAC scores were normalized to a 0-100 point scale for data analysis, where 0 is no pain and higher scores indicate greater pain, stiffness or difficulty in performing daily tasks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICOAP Scores (Dose Comparison)</measure>
    <time_frame>baseline, week 4</time_frame>
    <description>Change from baseline in Intermittent and Constant Osteoarthritis Pain (ICOAP) scores (score 0 [no pain]- 4 [extreme pain]). ICOAP scores were normalized to a 0-100 point scale, where 0 is no pain and higher scores indicate greater pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC Pain Weight-bearing Score and Non-weight-bearing Score (Dose Comparison)</measure>
    <time_frame>baseline, week 4</time_frame>
    <description>Changes from baseline in Western Ontario and McMasters Universities Osteoarthritis Index (WOMAC) pain weight-bearing score (questions 1,2, &amp; 5; score 0-30) and non-weight-bearing score (questions 3&amp;4; score 0-20) on target knee. The WOMAC scores were normalized to a 0-100 point scale for data analysis, where 0 is no pain and higher scores indicate greater pain, stiffness or difficulty in performing daily tasks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Function (Dose Comparison)</measure>
    <time_frame>baseline, week 4</time_frame>
    <description>Change in baseline assessed by the chair-stand test. The test measures the maximum number of chair stand repetitions possible in a 30-second period with out using the arms. Where 0 is no repetition completed and higher numbers corresponds to greater repetitions and physical function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC Total Score and WOMAC Function and Stiffness (Dose Comparison)</measure>
    <time_frame>baseline, week 4</time_frame>
    <description>Change from baseline in Western Ontario McMasters Universities Osteoarthritis Index (WOMAC) total score and WOMAC function (degree of difficulty experienced in performing daily activities - 17 questions score 0-170) and stiffness (the degree and timing of joint stiffness - 2 questions score 0-20). The WOMAC scores were normalized to a 0-100 point scale for data analysis, where 0 is no pain and higher scores indicate greater pain, stiffness or difficulty in performing daily tasks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of Osteoarthritis on Daily Living (PGA Score)</measure>
    <time_frame>baseline, week 4</time_frame>
    <description>Change from baseline in Impact of OA daily living assessed using Patient Global Assessment (PGA) score. PGA is scored on a 11-point scale from 0 (none) to 10 (extreme), where higher scores represents a higher level of disease activity or worse health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Productivity</measure>
    <time_frame>baseline, week 4</time_frame>
    <description>Change from baseline in work productivity and activity assessed by the Work Productivity and Active Impairment (WPAI scores 0-100% in four different categories: absenteeism, presenteeism, work productivity loss, and activity impairment). Outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life: EQ5D VAS Score</measure>
    <time_frame>baseline, week 4</time_frame>
    <description>The EuroQol-5 Domain (EQ-5D) is a standardized generic measure of health-related quality of life. The visual analog scale (VAS) is scored on a 0-100 scale, where 0 is &quot;the worst health you can imagine&quot; and 100, &quot;the best health you can imagine&quot;.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety Endpoint (Adverse Events)</measure>
    <time_frame>weeks 1 through 4</time_frame>
    <description>Nature, incidence and severity of AEs.</description>
  </other_outcome>
  <other_outcome>
    <measure>Skin Tolerability Assessment (Skin Reactions)</measure>
    <time_frame>week 4</time_frame>
    <description>Skin tolerability assessment, incidence of erythema at the application site. Grading scheme from 0-4 (0, normal skin, no erythema; 4, blister formation and/or necrosis).</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">444</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>AMZ001 + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>on the target knee</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMZ001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>on the target knee</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>on the target knee</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diclofenac gel on the target knee</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMZ001</intervention_name>
    <description>diclofenac gel</description>
    <arm_group_label>AMZ001</arm_group_label>
    <arm_group_label>AMZ001 + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator</intervention_name>
    <description>diclofenac gel</description>
    <arm_group_label>Comparator</arm_group_label>
    <other_name>active comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Osteoarthritis of the knee, according the American College of Rheumatology (ACR)&#xD;
             clinical and X-ray criteria.&#xD;
&#xD;
          2. Pain score rated on an 11-point numerical rating scale of the target knee of ≥ 20 and&#xD;
             ≤ 45 out of 50 in response to the WOMAC pain sub-score (5 questions), at the time of&#xD;
             screening, after washout of any pain relief medication.&#xD;
&#xD;
          3. Women of child-bearing potential must use at least an acceptably effective method of&#xD;
             contraception from enrollment up to at least 3 months after the study end.&#xD;
&#xD;
          4. Knee pain in the target knee for 14 days of the preceding month (knee pain due to&#xD;
             osteoarthritis and not due to another condition such as bursitis, tendinitis, etc.)&#xD;
             based on subject report.&#xD;
&#xD;
          5. On stable pain therapy (i.e., at least 3 days per week for the previous month) with an&#xD;
             oral or topical NSAID prescribed by physician for 30 days prior to the Screening Visit&#xD;
             and/or prescribed over-the-counter.&#xD;
&#xD;
          6. Except for osteoarthritis, in reasonably good health as determined by the&#xD;
             Investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known or suspected hypersensitivity to diclofenac, other non-steroidal&#xD;
             anti-inflammatory drugs or related substances including aspirin, any of the components&#xD;
             in either of the investigation products, or any physical impediment to gel application&#xD;
             on the target knee.&#xD;
&#xD;
          2. Injection of corticosteroids or hyaluronic acid in the target knee within 6 months of&#xD;
             screening or into any other joint within 30 days of screening.&#xD;
&#xD;
          3. High dose oral/injected corticosteroid treatment of more than 14 days during the past&#xD;
             6 months prior to screening.&#xD;
&#xD;
          4. Major surgery or arthroscopy of the target knee within the previous year prior to&#xD;
             screening.&#xD;
&#xD;
          5. Planned surgery of the target knee within the next 3 months.&#xD;
&#xD;
          6. Presence of an additional non-osteoarthritic disease affecting either knee, such as&#xD;
             rheumatoid arthritis, psoriasis, gout or pseudo-gout, if there is reason to believe&#xD;
             that the disease(s) may significantly interfere with the interpretation of the&#xD;
             clinical response to the study drug.&#xD;
&#xD;
          7. Medical history of coronary artery bypass graft surgery.&#xD;
&#xD;
          8. Current cancer or treatment for cancer within the past five years, with the exception&#xD;
             of non-melanoma skin cancer, unless affecting the target knee area.&#xD;
&#xD;
          9. Secondary osteoarthritis of the target knee, previous procedures or trauma affecting&#xD;
             joint of the target knee.&#xD;
&#xD;
         10. Reported incidence of any of the following diseases: known osteoarthritis of the&#xD;
             hip(s) if pain in hip(s) exceeds that of the target knee using the WOMAC Hip Pain&#xD;
             subscore, presence of significant back pain, or at least one migraine attack within&#xD;
             the past 12 months before screening, as reported by the subject.&#xD;
&#xD;
         11. Body Mass Index &gt; 45.0 kg/m2.&#xD;
&#xD;
         12. Generalized skin irritation, previous skin reactions upon use of topical NSAIDs,&#xD;
             current skin irritation or redness at the planned site of gel application, or&#xD;
             significant skin disease including psoriasis, as judged by the investigator.&#xD;
&#xD;
         13. Known presence of a ulcer or any gastrointestinal bleeding within 6 months prior to&#xD;
             screening.&#xD;
&#xD;
         14. Use of moderate or higher doses of opioid medication for the treatment of pain within&#xD;
             6 weeks before the screening visit.&#xD;
&#xD;
         15. Use of duloxetine, pregabalin, or gabapentin within 4 weeks before the screening&#xD;
             visit.&#xD;
&#xD;
         16. History of alcohol or drug abuse within the past year prior to randomization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Research Consulting</name>
      <address>
        <city>Milford</city>
        <state>Connecticut</state>
        <zip>06460</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Medical Associates</name>
      <address>
        <city>The Villages</city>
        <state>Florida</state>
        <zip>32162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Upstate Clinical Research Associates</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCR Brno, s.r.o</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCR Czech, a.s</name>
      <address>
        <city>Pardubice</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCR Prague s.r.o.</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanos Clinic</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 18, 2018</study_first_submitted>
  <study_first_submitted_qc>September 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2018</study_first_posted>
  <results_first_submitted>July 30, 2020</results_first_submitted>
  <results_first_submitted_qc>September 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 6, 2020</results_first_posted>
  <last_update_submitted>September 14, 2020</last_update_submitted>
  <last_update_submitted_qc>September 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AMZ001</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 5, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT03691844/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 22, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT03691844/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Seven trial sites in Denmark (1 site), Czech Republic (3 sites) and the USA (3 sites).&#xD;
Trial initiation: 04-Oct-2018 Trial completion: 09-Jul-2019</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>AMZ001 BID</title>
          <description>on the target knee&#xD;
AMZ001 gel twice daily.&#xD;
BID: Twice a day</description>
        </group>
        <group group_id="P2">
          <title>AMZ001 + Placebo QD</title>
          <description>on the target knee&#xD;
AMZ001 gel once daily, Placebo gel once daily.&#xD;
QD: Every day/daily</description>
        </group>
        <group group_id="P3">
          <title>Placebo BID</title>
          <description>on the target knee&#xD;
Placebo gel twice daily.&#xD;
BID: twice a day/ twice daily</description>
        </group>
        <group group_id="P4">
          <title>Voltaren 1% QID</title>
          <description>on the target knee&#xD;
Voltaren gel 1% applied 4 times a day&#xD;
QID: 4 times every day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="121"/>
                <participants group_id="P2" count="121"/>
                <participants group_id="P3" count="121"/>
                <participants group_id="P4" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="114"/>
                <participants group_id="P2" count="109"/>
                <participants group_id="P3" count="108"/>
                <participants group_id="P4" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AMZ001 BID</title>
          <description>on the target knee&#xD;
AMZ001 gel twice daily.&#xD;
BID: twice a day/twice daily</description>
        </group>
        <group group_id="B2">
          <title>AMZ001 + Placebo QD</title>
          <description>on the target knee&#xD;
AMZ001 gel once daily, Placebo gel once daily.&#xD;
QD: Every day/daily</description>
        </group>
        <group group_id="B3">
          <title>Placebo BID</title>
          <description>on the target knee&#xD;
Placebo gel twice daily.&#xD;
BID: 2 times a day/ twice a day</description>
        </group>
        <group group_id="B4">
          <title>Voltaren 1% QID</title>
          <description>on the target knee&#xD;
Voltaren gel 1% applied 4 times a day</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="121"/>
            <count group_id="B2" value="121"/>
            <count group_id="B3" value="121"/>
            <count group_id="B4" value="81"/>
            <count group_id="B5" value="444"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="216"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="77"/>
                    <measurement group_id="B4" value="54"/>
                    <measurement group_id="B5" value="297"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="118"/>
                    <measurement group_id="B4" value="80"/>
                    <measurement group_id="B5" value="439"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="115"/>
                    <measurement group_id="B4" value="77"/>
                    <measurement group_id="B5" value="426"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline WOMAC pain sub-score</title>
          <description>Baseline scores in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain sub-score (questions 1-5; score 0 [no pain]-50 [extreme pain]) on target knee. The WOMAC scores were normalized to a 0-100 point scale for data analysis, where higher scores indicates greater pain.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.2" spread="6.07"/>
                    <measurement group_id="B2" value="27.5" spread="5.24"/>
                    <measurement group_id="B3" value="27.1" spread="4.82"/>
                    <measurement group_id="B4" value="27.3" spread="5.48"/>
                    <measurement group_id="B5" value="27.5" spread="5.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>WOMAC Pain Sub-score</title>
        <description>Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain sub-score (questions 1-5; score 0 [no pain]-50 [extreme pain]) on target knee. The WOMAC scores were normalized to a 0-100 point scale for data analysis, where higher scores indicate greater pain, stiffness or difficulty in performing daily tasks.</description>
        <time_frame>baseline, week 4</time_frame>
        <population>The mITT (modified Intent to treat; N=120) population set includes subjects with a baseline and at least one post-treatment WOMAC pain sub-score and was used in statistical analysis for primary and secondary endpoint outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>AMZ001 BID</title>
            <description>AMZ001 gel twice daily</description>
          </group>
          <group group_id="O2">
            <title>AMZ001 + Placebo QD</title>
            <description>on the target knee&#xD;
AMZ001 gel once daily, Placebo gel once daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>Placebo gel twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>WOMAC Pain Sub-score</title>
          <description>Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain sub-score (questions 1-5; score 0 [no pain]-50 [extreme pain]) on target knee. The WOMAC scores were normalized to a 0-100 point scale for data analysis, where higher scores indicate greater pain, stiffness or difficulty in performing daily tasks.</description>
          <population>The mITT (modified Intent to treat; N=120) population set includes subjects with a baseline and at least one post-treatment WOMAC pain sub-score and was used in statistical analysis for primary and secondary endpoint outcome measures.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.49" lower_limit="-29.6" upper_limit="-23.38"/>
                    <measurement group_id="O2" value="-27.33" lower_limit="-30.5" upper_limit="-24.17"/>
                    <measurement group_id="O3" value="-22.73" lower_limit="-25.90" upper_limit="-19.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>WOMAC Total Score and WOMAC Function and Stiffness</title>
        <description>Change from baseline in Western Ontario McMasters Universities Osteoarthritis Index (WOMAC) total score and WOMAC function (degree of difficulty experienced in performing daily activities - 17 questions score 0-170) and stiffness (the degree and timing of joint stiffness - 2 questions score 0-20). The WOMAC scores were normalized to a 0-100 point scale for data analysis, where 0 is no pain and higher scores indicate greater pain, stiffness or difficulty in performing daily tasks.</description>
        <time_frame>baseline, week 4</time_frame>
        <population>The mITT (modified Intent to treat; N=120) population set includes subjects with a baseline and at least one post-treatment WOMAC pain sub-score and was used in statistical analysis for primary and secondary endpoint outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>AMZ001 BID</title>
            <description>on the target knee&#xD;
AMZ001 gel twice daily.</description>
          </group>
          <group group_id="O2">
            <title>AMZ001 + Placebo QD</title>
            <description>on the target knee&#xD;
AMZ001 gel once daily, Placebo gel once daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>on the target knee&#xD;
Placebo gel twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>WOMAC Total Score and WOMAC Function and Stiffness</title>
          <description>Change from baseline in Western Ontario McMasters Universities Osteoarthritis Index (WOMAC) total score and WOMAC function (degree of difficulty experienced in performing daily activities - 17 questions score 0-170) and stiffness (the degree and timing of joint stiffness - 2 questions score 0-20). The WOMAC scores were normalized to a 0-100 point scale for data analysis, where 0 is no pain and higher scores indicate greater pain, stiffness or difficulty in performing daily tasks.</description>
          <population>The mITT (modified Intent to treat; N=120) population set includes subjects with a baseline and at least one post-treatment WOMAC pain sub-score and was used in statistical analysis for primary and secondary endpoint outcome measures.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline WOMAC total score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.15" lower_limit="-26.95" upper_limit="-21.34"/>
                    <measurement group_id="O2" value="-23.32" lower_limit="-26.16" upper_limit="-20.47"/>
                    <measurement group_id="O3" value="-20.57" lower_limit="-23.42" upper_limit="-17.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline WOMAC function score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.43" lower_limit="-26.29" upper_limit="-20.58"/>
                    <measurement group_id="O2" value="-22.30" lower_limit="-25.19" upper_limit="-19.40"/>
                    <measurement group_id="O3" value="-19.94" lower_limit="-22.84" upper_limit="-17.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline WOMAC stiffness score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.17" lower_limit="-26.42" upper_limit="-19.93"/>
                    <measurement group_id="O2" value="-23.35" lower_limit="-26.66" upper_limit="-20.05"/>
                    <measurement group_id="O3" value="-20.65" lower_limit="-23.96" upper_limit="-17.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>WOMAC Pain Weight-bearing Score and Non-weight-bearing Score</title>
        <description>Change from baseline in Western Ontario McMasters Universities Osteoarthritis Index (WOMAC) pain weight-bearing score (questions 1,2, &amp; 5; score 0-30) and non-weight-bearing score (questions 3&amp;4; score 0-20) on target knee. The WOMAC scores were normalized to a 0-100 point scale for data analysis, where 0 is no pain and higher scores indicate greater pain, stiffness or difficulty in performing daily tasks.</description>
        <time_frame>baseline, week 4</time_frame>
        <population>The mITT (modified Intent to treat; N=120) population set includes subjects with a baseline and at least one post-treatment WOMAC pain sub-score and was used in statistical analysis for primary and secondary endpoint outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>AMZ001 BID</title>
            <description>on the target knee&#xD;
AMZ001 gel twice daily.</description>
          </group>
          <group group_id="O2">
            <title>AMZ001 + Placebo QD</title>
            <description>on the target knee&#xD;
AMZ001 gel once daily, Placebo gel once daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>on the target knee&#xD;
Placebo gel twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>WOMAC Pain Weight-bearing Score and Non-weight-bearing Score</title>
          <description>Change from baseline in Western Ontario McMasters Universities Osteoarthritis Index (WOMAC) pain weight-bearing score (questions 1,2, &amp; 5; score 0-30) and non-weight-bearing score (questions 3&amp;4; score 0-20) on target knee. The WOMAC scores were normalized to a 0-100 point scale for data analysis, where 0 is no pain and higher scores indicate greater pain, stiffness or difficulty in performing daily tasks.</description>
          <population>The mITT (modified Intent to treat; N=120) population set includes subjects with a baseline and at least one post-treatment WOMAC pain sub-score and was used in statistical analysis for primary and secondary endpoint outcome measures.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline WOMAC pain weight bearing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.03" lower_limit="-30.36" upper_limit="-23.70"/>
                    <measurement group_id="O2" value="-27.68" lower_limit="-31.07" upper_limit="-24.30"/>
                    <measurement group_id="O3" value="-22.65" lower_limit="-26.04" upper_limit="-19.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline WOMAC pain non-weight bearing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.65" lower_limit="-28.87" upper_limit="-22.44"/>
                    <measurement group_id="O2" value="-26.89" lower_limit="-30.17" upper_limit="-23.61"/>
                    <measurement group_id="O3" value="-22.93" lower_limit="-26.22" upper_limit="-19.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ICOAP Scores</title>
        <description>Change from baseline in Intermittent and Constant Osteoarthritis Pain (ICOAP) scores (score 0 [no pain]- 4 [extreme pain]). ICOAP scores were normalized to a 0-100 point scale, where 0 is no pain and higher scores indicate greater pain.</description>
        <time_frame>baseline, week 4</time_frame>
        <population>The mITT (modified Intent to treat; N=120) population set includes subjects with a baseline and at least one post-treatment WOMAC pain sub-score and was used in statistical analysis for primary and secondary endpoint outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>AMZ001 BID</title>
            <description>on the target knee&#xD;
AMZ001 gel twice daily.</description>
          </group>
          <group group_id="O2">
            <title>AMZ001 + Placebo QD</title>
            <description>on the target knee&#xD;
AMZ001 gel once daily, Placebo gel once daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>on the target knee&#xD;
Placebo gel twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>ICOAP Scores</title>
          <description>Change from baseline in Intermittent and Constant Osteoarthritis Pain (ICOAP) scores (score 0 [no pain]- 4 [extreme pain]). ICOAP scores were normalized to a 0-100 point scale, where 0 is no pain and higher scores indicate greater pain.</description>
          <population>The mITT (modified Intent to treat; N=120) population set includes subjects with a baseline and at least one post-treatment WOMAC pain sub-score and was used in statistical analysis for primary and secondary endpoint outcome measures.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ICOAP total score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.62" lower_limit="-23.40" upper_limit="-17.84"/>
                    <measurement group_id="O2" value="-18.87" lower_limit="-21.72" upper_limit="-16.02"/>
                    <measurement group_id="O3" value="-17.98" lower_limit="-20.83" upper_limit="-15.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICOAP constant pain score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.82" lower_limit="-23.91" upper_limit="-17.73"/>
                    <measurement group_id="O2" value="-19.01" lower_limit="-22.18" upper_limit="-15.83"/>
                    <measurement group_id="O3" value="-18.37" lower_limit="-21.54" upper_limit="-15.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICOAP intermittent pain score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.18" lower_limit="-23.19" upper_limit="-17.17"/>
                    <measurement group_id="O2" value="-19.00" lower_limit="-22.09" upper_limit="-15.92"/>
                    <measurement group_id="O3" value="-17.99" lower_limit="-21.08" upper_limit="-14.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physical Function</title>
        <description>Change in baseline in physical function assessed by the chair-stand test. The test measures the maximum number of chair stand repetitions possible in a 30-second period with out using the arms. Where 0 is no repetition completed and higher numbers corresponds to greater repetitions and physical function.</description>
        <time_frame>baseline, week 4</time_frame>
        <population>The mITT (modified Intent to treat; N=120) population set includes subjects with a baseline and at least one post-treatment WOMAC pain sub-score and was used in statistical analysis for primary and secondary endpoint outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>AMZ001 BID</title>
            <description>on the target knee&#xD;
AMZ001 gel twice daily.</description>
          </group>
          <group group_id="O2">
            <title>AMZ001 + Placebo QD</title>
            <description>on the target knee&#xD;
AMZ001 gel once daily, Placebo gel once daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>on the target knee&#xD;
Placebo gel twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Physical Function</title>
          <description>Change in baseline in physical function assessed by the chair-stand test. The test measures the maximum number of chair stand repetitions possible in a 30-second period with out using the arms. Where 0 is no repetition completed and higher numbers corresponds to greater repetitions and physical function.</description>
          <population>The mITT (modified Intent to treat; N=120) population set includes subjects with a baseline and at least one post-treatment WOMAC pain sub-score and was used in statistical analysis for primary and secondary endpoint outcome measures.</population>
          <units>repetitions</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.41" lower_limit="1.98" upper_limit="2.83"/>
                    <measurement group_id="O2" value="2.30" lower_limit="1.87" upper_limit="2.72"/>
                    <measurement group_id="O3" value="2.37" lower_limit="1.94" upper_limit="2.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Responders as Per OMERACT-OARSI Criteria</title>
        <description>Outcome Measures in Rheumatology- Osteoarthritis Research Society International (OMERACT-OARSI) response involves changes that are deemed to be clinically relevant in three domains: pain, function, and PGA (Patient Global Assessment). For each of these domains, ranges are defined for absolute and percent changes from baseline that correspond to &quot;high improvement&quot; and &quot;moderate improvement&quot;. OMERACT-OARSI response is defined as either high improvement in at least 1 of WOMAC pain and function scores OR moderate improvement in at least 2 of WOMAC pain scores, WOMAC function score or Patient Global Assessment (PGA)</description>
        <time_frame>week 4</time_frame>
        <population>The mITT (modified Intent to treat; N=120) population set includes subjects with a baseline and at least one post-treatment WOMAC pain sub-score and was used in statistical analysis for primary and secondary endpoint outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>AMZ001 BID</title>
            <description>on the target knee&#xD;
AMZ001 gel twice daily.</description>
          </group>
          <group group_id="O2">
            <title>AMZ001 + Placebo QD</title>
            <description>on the target knee&#xD;
AMZ001 gel once daily, Placebo gel once daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>on the target knee&#xD;
Placebo gel twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Responders as Per OMERACT-OARSI Criteria</title>
          <description>Outcome Measures in Rheumatology- Osteoarthritis Research Society International (OMERACT-OARSI) response involves changes that are deemed to be clinically relevant in three domains: pain, function, and PGA (Patient Global Assessment). For each of these domains, ranges are defined for absolute and percent changes from baseline that correspond to &quot;high improvement&quot; and &quot;moderate improvement&quot;. OMERACT-OARSI response is defined as either high improvement in at least 1 of WOMAC pain and function scores OR moderate improvement in at least 2 of WOMAC pain scores, WOMAC function score or Patient Global Assessment (PGA)</description>
          <population>The mITT (modified Intent to treat; N=120) population set includes subjects with a baseline and at least one post-treatment WOMAC pain sub-score and was used in statistical analysis for primary and secondary endpoint outcome measures.</population>
          <units>Proportion of responders</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.765" lower_limit="0.679" upper_limit="0.834"/>
                    <measurement group_id="O2" value="0.826" lower_limit=".0743" upper_limit="0.886"/>
                    <measurement group_id="O3" value="0.725" lower_limit="0.634" upper_limit="0.800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Dose of Rescue Medication</title>
        <description>Total dose of rescue medication calculated as the average gram use/day, based on pill counts.</description>
        <time_frame>weeks 1 through 4</time_frame>
        <population>The mITT (modified Intent to treat; N=120) population set includes subjects with a baseline and at least one post-treatment WOMAC pain sub-score and was used in statistical analysis for primary and secondary endpoint outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>AMZ001 BID</title>
            <description>on the target knee&#xD;
AMZ001 gel twice daily.</description>
          </group>
          <group group_id="O2">
            <title>AMZ001 + Placebo QD</title>
            <description>on the target knee&#xD;
AMZ001 gel once daily, Placebo gel once daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>on the target knee&#xD;
Placebo gel twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Dose of Rescue Medication</title>
          <description>Total dose of rescue medication calculated as the average gram use/day, based on pill counts.</description>
          <population>The mITT (modified Intent to treat; N=120) population set includes subjects with a baseline and at least one post-treatment WOMAC pain sub-score and was used in statistical analysis for primary and secondary endpoint outcome measures.</population>
          <units>gram/day</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" lower_limit="0.19" upper_limit="0.36"/>
                    <measurement group_id="O2" value="0.31" lower_limit="0.22" upper_limit="0.40"/>
                    <measurement group_id="O3" value="0.30" lower_limit="0.21" upper_limit="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Between Baseline and First Use of Rescue Medication</title>
        <description>Time between baseline and first use of rescue medication.</description>
        <time_frame>weeks 1 through 4</time_frame>
        <population>The mITT (modified Intent to treat; N=120) population set includes subjects with a baseline and at least one post-treatment WOMAC pain sub-score and was used in statistical analysis for primary and secondary endpoint outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>AMZ001 BID</title>
            <description>on the target knee&#xD;
AMZ001 gel twice daily.</description>
          </group>
          <group group_id="O2">
            <title>AMZ001 + Placebo QD</title>
            <description>on the target knee&#xD;
AMZ001 gel once daily, Placebo gel once daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>on the target knee&#xD;
Placebo gel twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Time Between Baseline and First Use of Rescue Medication</title>
          <description>Time between baseline and first use of rescue medication.</description>
          <population>The mITT (modified Intent to treat; N=120) population set includes subjects with a baseline and at least one post-treatment WOMAC pain sub-score and was used in statistical analysis for primary and secondary endpoint outcome measures.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="7.0" upper_limit="24.0"/>
                    <measurement group_id="O2" value="9" lower_limit="5.0" upper_limit="15.0"/>
                    <measurement group_id="O3" value="10" lower_limit="4.0" upper_limit="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>WOMAC Pain Sub-score (Dose Comparison)</title>
        <description>Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain sub-score (questions 1-5; score 0 [no pain]-50 [extreme pain]) on target knee. The WOMAC scores were normalized to a 0-100 point scale for data analysis, where 0 is no pain and higher scores indicate greater pain, stiffness or difficulty in performing daily tasks.</description>
        <time_frame>baseline, week 4</time_frame>
        <population>The mITT (modified Intent to treat; N=120) population set includes subjects with a baseline and at least one post-treatment WOMAC pain sub-score and was used in statistical analysis for primary and secondary endpoint outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>AMZ001 BID</title>
            <description>on the target knee&#xD;
AMZ001 gel twice daily.</description>
          </group>
          <group group_id="O2">
            <title>AMZ001 + Placebo QD</title>
            <description>on the target knee&#xD;
AMZ001 gel once daily, Placebo gel once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>WOMAC Pain Sub-score (Dose Comparison)</title>
          <description>Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain sub-score (questions 1-5; score 0 [no pain]-50 [extreme pain]) on target knee. The WOMAC scores were normalized to a 0-100 point scale for data analysis, where 0 is no pain and higher scores indicate greater pain, stiffness or difficulty in performing daily tasks.</description>
          <population>The mITT (modified Intent to treat; N=120) population set includes subjects with a baseline and at least one post-treatment WOMAC pain sub-score and was used in statistical analysis for primary and secondary endpoint outcome measures.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.49" lower_limit="-29.60" upper_limit="-23.38"/>
                    <measurement group_id="O2" value="-27.33" lower_limit="-30.5" upper_limit="-24.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ICOAP Scores (Dose Comparison)</title>
        <description>Change from baseline in Intermittent and Constant Osteoarthritis Pain (ICOAP) scores (score 0 [no pain]- 4 [extreme pain]). ICOAP scores were normalized to a 0-100 point scale, where 0 is no pain and higher scores indicate greater pain.</description>
        <time_frame>baseline, week 4</time_frame>
        <population>The mITT (modified Intent to treat; N=120) population set includes subjects with a baseline and at least one post-treatment WOMAC pain sub-score and was used in statistical analysis for primary and secondary endpoint outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>AMZ001 BID</title>
            <description>on the target knee&#xD;
AMZ001 gel twice daily.</description>
          </group>
          <group group_id="O2">
            <title>AMZ001 + Placebo QD</title>
            <description>on the target knee&#xD;
AMZ001 gel once daily, Placebo gel once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>ICOAP Scores (Dose Comparison)</title>
          <description>Change from baseline in Intermittent and Constant Osteoarthritis Pain (ICOAP) scores (score 0 [no pain]- 4 [extreme pain]). ICOAP scores were normalized to a 0-100 point scale, where 0 is no pain and higher scores indicate greater pain.</description>
          <population>The mITT (modified Intent to treat; N=120) population set includes subjects with a baseline and at least one post-treatment WOMAC pain sub-score and was used in statistical analysis for primary and secondary endpoint outcome measures.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.62" lower_limit="-23.40" upper_limit="-17.84"/>
                    <measurement group_id="O2" value="-18.87" lower_limit="-21.72" upper_limit="-16.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>WOMAC Pain Weight-bearing Score and Non-weight-bearing Score (Dose Comparison)</title>
        <description>Changes from baseline in Western Ontario and McMasters Universities Osteoarthritis Index (WOMAC) pain weight-bearing score (questions 1,2, &amp; 5; score 0-30) and non-weight-bearing score (questions 3&amp;4; score 0-20) on target knee. The WOMAC scores were normalized to a 0-100 point scale for data analysis, where 0 is no pain and higher scores indicate greater pain, stiffness or difficulty in performing daily tasks.</description>
        <time_frame>baseline, week 4</time_frame>
        <population>The mITT (modified Intent to treat; N=120) population set includes subjects with a baseline and at least one post-treatment WOMAC pain sub-score and was used in statistical analysis for primary and secondary endpoint outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>AMZ001 BID</title>
            <description>on the target knee&#xD;
AMZ001 gel twice daily.</description>
          </group>
          <group group_id="O2">
            <title>AMZ001 + Placebo QD</title>
            <description>on the target knee&#xD;
AMZ001 gel once daily, Placebo gel once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>WOMAC Pain Weight-bearing Score and Non-weight-bearing Score (Dose Comparison)</title>
          <description>Changes from baseline in Western Ontario and McMasters Universities Osteoarthritis Index (WOMAC) pain weight-bearing score (questions 1,2, &amp; 5; score 0-30) and non-weight-bearing score (questions 3&amp;4; score 0-20) on target knee. The WOMAC scores were normalized to a 0-100 point scale for data analysis, where 0 is no pain and higher scores indicate greater pain, stiffness or difficulty in performing daily tasks.</description>
          <population>The mITT (modified Intent to treat; N=120) population set includes subjects with a baseline and at least one post-treatment WOMAC pain sub-score and was used in statistical analysis for primary and secondary endpoint outcome measures.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Weight-bearing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.03" lower_limit="-30.36" upper_limit="-23.70"/>
                    <measurement group_id="O2" value="-27.68" lower_limit="-31.07" upper_limit="-24.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-weight-bearing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.65" lower_limit="-28.87" upper_limit="-22.44"/>
                    <measurement group_id="O2" value="-26.89" lower_limit="-30.17" upper_limit="-23.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physical Function (Dose Comparison)</title>
        <description>Change in baseline assessed by the chair-stand test. The test measures the maximum number of chair stand repetitions possible in a 30-second period with out using the arms. Where 0 is no repetition completed and higher numbers corresponds to greater repetitions and physical function.</description>
        <time_frame>baseline, week 4</time_frame>
        <population>The mITT (modified Intent to treat; N=120) population set includes subjects with a baseline and at least one post-treatment WOMAC pain sub-score and was used in statistical analysis for primary and secondary endpoint outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>AMZ001 BID</title>
            <description>on the target knee&#xD;
AMZ001 gel twice daily.</description>
          </group>
          <group group_id="O2">
            <title>AMZ001 + Placebo QD</title>
            <description>on the target knee&#xD;
AMZ001 gel once daily, Placebo gel once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Physical Function (Dose Comparison)</title>
          <description>Change in baseline assessed by the chair-stand test. The test measures the maximum number of chair stand repetitions possible in a 30-second period with out using the arms. Where 0 is no repetition completed and higher numbers corresponds to greater repetitions and physical function.</description>
          <population>The mITT (modified Intent to treat; N=120) population set includes subjects with a baseline and at least one post-treatment WOMAC pain sub-score and was used in statistical analysis for primary and secondary endpoint outcome measures.</population>
          <units>repetitions</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.41" lower_limit="1.98" upper_limit="2.83"/>
                    <measurement group_id="O2" value="2.3" lower_limit="1.87" upper_limit="2.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>WOMAC Total Score and WOMAC Function and Stiffness (Dose Comparison)</title>
        <description>Change from baseline in Western Ontario McMasters Universities Osteoarthritis Index (WOMAC) total score and WOMAC function (degree of difficulty experienced in performing daily activities - 17 questions score 0-170) and stiffness (the degree and timing of joint stiffness - 2 questions score 0-20). The WOMAC scores were normalized to a 0-100 point scale for data analysis, where 0 is no pain and higher scores indicate greater pain, stiffness or difficulty in performing daily tasks.</description>
        <time_frame>baseline, week 4</time_frame>
        <population>The mITT (modified Intent to treat; N=120) population set includes subjects with a baseline and at least one post-treatment WOMAC pain sub-score and was used in statistical analysis for primary and secondary endpoint outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>AMZ001 BID</title>
            <description>on the target knee&#xD;
AMZ001 gel twice daily.</description>
          </group>
          <group group_id="O2">
            <title>AMZ001 + Placebo QD</title>
            <description>on the target knee&#xD;
AMZ001 gel once daily, Placebo gel once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>WOMAC Total Score and WOMAC Function and Stiffness (Dose Comparison)</title>
          <description>Change from baseline in Western Ontario McMasters Universities Osteoarthritis Index (WOMAC) total score and WOMAC function (degree of difficulty experienced in performing daily activities - 17 questions score 0-170) and stiffness (the degree and timing of joint stiffness - 2 questions score 0-20). The WOMAC scores were normalized to a 0-100 point scale for data analysis, where 0 is no pain and higher scores indicate greater pain, stiffness or difficulty in performing daily tasks.</description>
          <population>The mITT (modified Intent to treat; N=120) population set includes subjects with a baseline and at least one post-treatment WOMAC pain sub-score and was used in statistical analysis for primary and secondary endpoint outcome measures.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.43" lower_limit="-26.29" upper_limit="-20.58"/>
                    <measurement group_id="O2" value="-22.30" lower_limit="-25.19" upper_limit="-19.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stiffness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.17" lower_limit="-26.42" upper_limit="-19.93"/>
                    <measurement group_id="O2" value="-23.35" lower_limit="-26.66" upper_limit="-20.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Impact of Osteoarthritis on Daily Living (PGA Score)</title>
        <description>Change from baseline in Impact of OA daily living assessed using Patient Global Assessment (PGA) score. PGA is scored on a 11-point scale from 0 (none) to 10 (extreme), where higher scores represents a higher level of disease activity or worse health.</description>
        <time_frame>baseline, week 4</time_frame>
        <population>The mITT (modified Intent to treat; N=120) population set includes subjects with a baseline and at least one post-treatment WOMAC pain sub-score and was used in statistical analysis for primary and secondary endpoint outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>AMZ001 BID</title>
            <description>on the target knee&#xD;
AMZ001 gel twice daily.</description>
          </group>
          <group group_id="O2">
            <title>AMZ001 + Placebo QD</title>
            <description>on the target knee&#xD;
AMZ001 gel once daily, Placebo gel once daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>on the target knee&#xD;
Placebo gel twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Impact of Osteoarthritis on Daily Living (PGA Score)</title>
          <description>Change from baseline in Impact of OA daily living assessed using Patient Global Assessment (PGA) score. PGA is scored on a 11-point scale from 0 (none) to 10 (extreme), where higher scores represents a higher level of disease activity or worse health.</description>
          <population>The mITT (modified Intent to treat; N=120) population set includes subjects with a baseline and at least one post-treatment WOMAC pain sub-score and was used in statistical analysis for primary and secondary endpoint outcome measures.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.29" lower_limit="-2.63" upper_limit="-1.94"/>
                    <measurement group_id="O2" value="-2.31" lower_limit="-2.66" upper_limit="-1.96"/>
                    <measurement group_id="O3" value="-1.68" lower_limit="-2.03" upper_limit="-1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Work Productivity</title>
        <description>Change from baseline in work productivity and activity assessed by the Work Productivity and Active Impairment (WPAI scores 0-100% in four different categories: absenteeism, presenteeism, work productivity loss, and activity impairment). Outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.</description>
        <time_frame>baseline, week 4</time_frame>
        <population>The mITT (modified Intent to treat; N=120) population set includes subjects with a baseline and at least one post-treatment WOMAC pain sub-score and was used in statistical analysis for primary and secondary endpoint outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>AMZ001 BID</title>
            <description>on the target knee&#xD;
AMZ001 gel twice daily.</description>
          </group>
          <group group_id="O2">
            <title>AMZ001 + Placebo QD</title>
            <description>on the target knee&#xD;
AMZ001 gel once daily, Placebo gel once daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>on the target knee&#xD;
Placebo gel twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Work Productivity</title>
          <description>Change from baseline in work productivity and activity assessed by the Work Productivity and Active Impairment (WPAI scores 0-100% in four different categories: absenteeism, presenteeism, work productivity loss, and activity impairment). Outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.</description>
          <population>The mITT (modified Intent to treat; N=120) population set includes subjects with a baseline and at least one post-treatment WOMAC pain sub-score and was used in statistical analysis for primary and secondary endpoint outcome measures.</population>
          <units>percentage of impairment</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>WPAI % Time missed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" lower_limit="-2.73" upper_limit="3.51"/>
                    <measurement group_id="O2" value="-3.10" lower_limit="-6.43" upper_limit="0.23"/>
                    <measurement group_id="O3" value="1.58" lower_limit="-2.01" upper_limit="5.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WPAI % Impairment while working</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.11" lower_limit="-18.71" upper_limit="-7.51"/>
                    <measurement group_id="O2" value="-14.38" lower_limit="-20.57" upper_limit="-8.79"/>
                    <measurement group_id="O3" value="-5.28" lower_limit="-12.26" upper_limit="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WPAI % Overall work impairment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.69" lower_limit="-17.95" upper_limit="-5.43"/>
                    <measurement group_id="O2" value="-16.93" lower_limit="-23.95" upper_limit="-9.91"/>
                    <measurement group_id="O3" value="-6.50" lower_limit="-14.19" upper_limit="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WPAI % Activity impairment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.75" lower_limit="-21.45" upper_limit="-14.06"/>
                    <measurement group_id="O2" value="-20.41" lower_limit="-24.15" upper_limit="-16.68"/>
                    <measurement group_id="O3" value="-13.03" lower_limit="-16.79" upper_limit="-9.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life: EQ5D VAS Score</title>
        <description>The EuroQol-5 Domain (EQ-5D) is a standardized generic measure of health-related quality of life. The visual analog scale (VAS) is scored on a 0-100 scale, where 0 is &quot;the worst health you can imagine&quot; and 100, &quot;the best health you can imagine&quot;.</description>
        <time_frame>baseline, week 4</time_frame>
        <population>The mITT (modified Intent to treat; N=120) population set includes subjects with a baseline and at least one post-treatment WOMAC pain sub-score and was used in statistical analysis for primary and secondary endpoint outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>AMZ001 BID</title>
            <description>on the target knee&#xD;
AMZ001 gel twice daily.</description>
          </group>
          <group group_id="O2">
            <title>AMZ001 + Placebo QD</title>
            <description>on the target knee&#xD;
AMZ001 gel once daily, Placebo gel once daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>on the target knee&#xD;
Placebo gel twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life: EQ5D VAS Score</title>
          <description>The EuroQol-5 Domain (EQ-5D) is a standardized generic measure of health-related quality of life. The visual analog scale (VAS) is scored on a 0-100 scale, where 0 is &quot;the worst health you can imagine&quot; and 100, &quot;the best health you can imagine&quot;.</description>
          <population>The mITT (modified Intent to treat; N=120) population set includes subjects with a baseline and at least one post-treatment WOMAC pain sub-score and was used in statistical analysis for primary and secondary endpoint outcome measures.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.04" lower_limit="10.13" upper_limit="15.94"/>
                    <measurement group_id="O2" value="11.76" lower_limit="8.82" upper_limit="14.71"/>
                    <measurement group_id="O3" value="8.34" lower_limit="5.39" upper_limit="11.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Safety Endpoint (Adverse Events)</title>
        <description>Nature, incidence and severity of AEs.</description>
        <time_frame>weeks 1 through 4</time_frame>
        <population>The SAF (Safety Analysis Set; N=121) was used for safety evaluation of adverse events.</population>
        <group_list>
          <group group_id="O1">
            <title>AMZ001 BID</title>
            <description>on the target knee&#xD;
AMZ001 gel twice daily.</description>
          </group>
          <group group_id="O2">
            <title>AMZ001 + Placebo QD</title>
            <description>on the target knee&#xD;
AMZ001 gel once daily, Placebo gel once daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>on the target knee&#xD;
Placebo gel twice daily.</description>
          </group>
          <group group_id="O4">
            <title>Voltaren 1% QID</title>
            <description>on the target knee Voltaren gel 1% applied 4 times a day QID: 4 times every day</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Endpoint (Adverse Events)</title>
          <description>Nature, incidence and severity of AEs.</description>
          <population>The SAF (Safety Analysis Set; N=121) was used for safety evaluation of adverse events.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="121"/>
                <count group_id="O3" value="121"/>
                <count group_id="O4" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="75"/>
                    <measurement group_id="O4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to treatment discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="51"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="66"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Skin Tolerability Assessment (Skin Reactions)</title>
        <description>Skin tolerability assessment, incidence of erythema at the application site. Grading scheme from 0-4 (0, normal skin, no erythema; 4, blister formation and/or necrosis).</description>
        <time_frame>week 4</time_frame>
        <population>Nature, incidence and severity of AEs. The SAF (Safety Analysis Set; N=121) was used for safety evaluation of adverse events.</population>
        <group_list>
          <group group_id="O1">
            <title>AMZ001 BID</title>
            <description>on the target knee&#xD;
AMZ001 gel twice daily.</description>
          </group>
          <group group_id="O2">
            <title>AMZ001 + Placebo QD</title>
            <description>on the target knee&#xD;
AMZ001 gel once daily, Placebo gel once daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>on the target knee&#xD;
Placebo gel twice daily.</description>
          </group>
          <group group_id="O4">
            <title>Voltaren 1% QID</title>
            <description>on the target knee Voltaren gel 1% applied 4 times a day QID: 4 times every day</description>
          </group>
        </group_list>
        <measure>
          <title>Skin Tolerability Assessment (Skin Reactions)</title>
          <description>Skin tolerability assessment, incidence of erythema at the application site. Grading scheme from 0-4 (0, normal skin, no erythema; 4, blister formation and/or necrosis).</description>
          <population>Nature, incidence and severity of AEs. The SAF (Safety Analysis Set; N=121) was used for safety evaluation of adverse events.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="121"/>
                <count group_id="O3" value="121"/>
                <count group_id="O4" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal skin; no erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="89"/>
                    <measurement group_id="O3" value="79"/>
                    <measurement group_id="O4" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Questionable erythema not covering entire app site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite erythema not covering entire app site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite erythema and swelling or induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blister formation and/or necrosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>WOMAC Pain Sub-score (Subgroup With WOMAC Normalized Pain Sub-score ≥40 at Baseline)</title>
        <description>Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain sub-score (questions 1-5; score 0 [no pain]-50 [extreme pain]) on target knee. The WOMAC scores were normalized to a 0-100 point scale for data analysis. The WOMAC scores were normalized to a 0-100 point scale for data analysis, where 0 is no pain and higher scores indicate greater pain, stiffness or difficulty in performing daily tasks.</description>
        <time_frame>baseline, week 4</time_frame>
        <population>Post-hoc statistical analyses were performed for the comparison of each of the AMZ001 regimens vs placebo and between the two AMZ001 regimens. Sub-group of subjects meeting the WOMAC pain sub-score inclusion criterion at both screening and baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>AMZ001 BID</title>
            <description>on the target knee&#xD;
AMZ001 gel twice daily.</description>
          </group>
          <group group_id="O2">
            <title>AMZ001 + Placebo QD</title>
            <description>on the target knee&#xD;
AMZ001 gel once daily, Placebo gel once daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>on the target knee&#xD;
Placebo gel twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>WOMAC Pain Sub-score (Subgroup With WOMAC Normalized Pain Sub-score ≥40 at Baseline)</title>
          <description>Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain sub-score (questions 1-5; score 0 [no pain]-50 [extreme pain]) on target knee. The WOMAC scores were normalized to a 0-100 point scale for data analysis. The WOMAC scores were normalized to a 0-100 point scale for data analysis, where 0 is no pain and higher scores indicate greater pain, stiffness or difficulty in performing daily tasks.</description>
          <population>Post-hoc statistical analyses were performed for the comparison of each of the AMZ001 regimens vs placebo and between the two AMZ001 regimens. Sub-group of subjects meeting the WOMAC pain sub-score inclusion criterion at both screening and baseline.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.54" lower_limit="-31.87" upper_limit="-25.20"/>
                    <measurement group_id="O2" value="-29.02" lower_limit="-32.45" upper_limit="-25.60"/>
                    <measurement group_id="O3" value="-23.18" lower_limit="-26.64" upper_limit="-19.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>WOMAC Total Score and WOMAC Function and Stiffness (Subgroup With WOMAC Normalized Pain Sub-score ≥40 at Baseline)</title>
        <description>Change from baseline in Western Ontario McMasters Universities Osteoarthritis Index (WOMAC) total score and WOMAC function (degree of difficulty experienced in performing daily activities - 17 questions score 0-170) and stiffness (the degree and timing of joint stiffness - 2 questions score 0-20) . The WOMAC scores were normalized to a 0-100 point scale for data analysis, where 0 is no pain and higher scores indicate greater pain, stiffness or difficulty in performing daily tasks.</description>
        <time_frame>baseline, week 4</time_frame>
        <population>Post-hoc statistical analyses were performed for the comparison of each of the AMZ001 regimens vs placebo and between the two AMZ001 regimens. Sub-group of subjects meeting the WOMAC pain sub-score inclusion criterion at both screening and baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>AMZ001 BID</title>
            <description>on the target knee&#xD;
AMZ001 gel twice daily.</description>
          </group>
          <group group_id="O2">
            <title>AMZ001 + Placebo QD</title>
            <description>on the target knee&#xD;
AMZ001 gel once daily, Placebo gel once daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>on the target knee&#xD;
Placebo gel twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>WOMAC Total Score and WOMAC Function and Stiffness (Subgroup With WOMAC Normalized Pain Sub-score ≥40 at Baseline)</title>
          <description>Change from baseline in Western Ontario McMasters Universities Osteoarthritis Index (WOMAC) total score and WOMAC function (degree of difficulty experienced in performing daily activities - 17 questions score 0-170) and stiffness (the degree and timing of joint stiffness - 2 questions score 0-20) . The WOMAC scores were normalized to a 0-100 point scale for data analysis, where 0 is no pain and higher scores indicate greater pain, stiffness or difficulty in performing daily tasks.</description>
          <population>Post-hoc statistical analyses were performed for the comparison of each of the AMZ001 regimens vs placebo and between the two AMZ001 regimens. Sub-group of subjects meeting the WOMAC pain sub-score inclusion criterion at both screening and baseline.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline WOMAC total score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.54" lower_limit="-28.54" upper_limit="-22.54"/>
                    <measurement group_id="O2" value="-24.03" lower_limit="-27.11" upper_limit="-20.95"/>
                    <measurement group_id="O3" value="-20.61" lower_limit="-23.71" upper_limit="-17.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline WOMAC function score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.69" lower_limit="-27.75" upper_limit="-21.64"/>
                    <measurement group_id="O2" value="-22.84" lower_limit="-25.97" upper_limit="-19.70"/>
                    <measurement group_id="O3" value="-19.84" lower_limit="-23.00" upper_limit="-16.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline WOMAC stiffness score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.08" lower_limit="-27.52" upper_limit="-20.64"/>
                    <measurement group_id="O2" value="-23.57" lower_limit="-27.11" upper_limit="-20.03"/>
                    <measurement group_id="O3" value="-20.33" lower_limit="-23.89" upper_limit="-16.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 Weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>AMZ001 BID</title>
          <description>AMZ001 gel twice daily</description>
        </group>
        <group group_id="E2">
          <title>AMZ001 + Placebo QD</title>
          <description>on the target knee&#xD;
AMZ001 gel once daily, Placebo gel once daily.</description>
        </group>
        <group group_id="E3">
          <title>Placebo BID</title>
          <description>Placebo gel twice daily</description>
        </group>
        <group group_id="E4">
          <title>Voltaren 1% QID</title>
          <description>on the target knee&#xD;
Voltaren gel 1% applied 4 times a day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="121"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="121"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application Site erythema</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="121"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="121"/>
                <counts group_id="E3" events="41" subjects_affected="40" subjects_at_risk="121"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Application site dryness</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="121"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="121"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="121"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="121"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="121"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="121"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="121"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="121"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="121"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="121"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="121"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Manager</name_or_title>
      <organization>Amzell B.V.</organization>
      <phone>+41614864000</phone>
      <email>amzell-disclosure@amzell.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

